Market Research Logo

Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2027

1. Key Insights
2. Neuroendocrine Tumors Epidemiology Overview at a Glance
2.1. Market (%) Distribution of Neuroendocrine Tumors in 2017
2.2. Market (%) Distribution of Neuroendocrine Tumors in 2027
3. Disease Background and Overview: Neuroendocrine Tumors (NET)
3.1. Introduction
3.2. Classification of Neuroendocrine Tumors
3.3. Causes
3.4. Risk Factors
3.5. Symptoms
3.6. Pathophysiology
3.7. Diagnosis
3.7.1. Grading of NETs
3.7.2. Staging of NETs
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of NETs
4.3. Total Incident Patient Population of NETs
4.4. Country Wise-Epidemiology of NETs
4.5. United States
4.5.1. Total Prevalent Cases of NETs in the United States
4.5.2. Total Incident Cases of NETs in the United States
4.5.3. Diagnosed prevalent cases of NETs in the United States
4.5.4. Symptom based classification of NETs
4.5.5. Diagnosed prevalent cases based on Malignancy
4.5.6. Site-specific prevalent cases of NETs
4.5.7. Grade-wise prevalent cases of NETs
4.5.8. Stage-wise prevalent cases of NETs
4.6. EU5 Countries
4.7. Germany
4.7.1. Total Prevalent Cases of NETs in Germany
4.7.2. Total Incident Cases of NETs in Germany
4.7.3. Diagnosed prevalent cases of NETs in Germany
4.7.4. Symptom based classification of NETs
4.7.5. Diagnosed prevalent cases based on Malignancy
4.7.6. Site-specific prevalent cases of NETs
4.7.7. Grade-wise prevalent cases of NETs
4.7.8. Stage-wise prevalent cases of NETs
4.8. France
4.8.1. Total Prevalent Cases of NETs in France
4.8.2. Total Incident Cases of NETs in France
4.8.3. Diagnosed prevalent cases of NETs in France
4.8.4. Symptom based classification of NETs
4.8.5. Diagnosed prevalent cases based on Malignancy
4.8.6. Site-specific prevalent cases of NETs
4.8.7. Grade-wise prevalent cases of NETs
4.8.8. Stage-wise prevalent cases of NETs
4.9. Italy
4.9.1. Total Prevalent Cases of NETs in Italy
4.9.2. Total Incident Cases of NETs in Italy
4.9.3. Diagnosed prevalent cases of NETs in Italy
4.9.4. Symptom based classification of NETs
4.9.5. Diagnosed prevalent cases based on Malignancy
4.9.6. Site-specific prevalent cases of NETs
4.9.7. Grade-wise prevalent cases of NETs
4.9.8. Stage-wise prevalent cases of NETs
4.10. Spain
4.10.1. Total Prevalent Cases of NETs in Spain
4.10.2. Total Incident Cases of NETs in Spain
4.10.3. Diagnosed prevalent cases of NETs in Spain
4.10.4. Symptom based classification of NETs
4.10.5. Diagnosed prevalent cases based on Malignancy
4.10.6. Site-specific prevalent cases of NETs
4.10.7. Grade-wise prevalent cases of NETs
4.10.8. Stage-wise prevalent cases of NETs
4.11. United Kingdom
4.11.1. Total Prevalent Cases of NETs in the UK
4.11.2. Total Incident Cases of NETs in the UK
4.11.3. Diagnosed prevalent cases of NETs in the UK
4.11.4. Symptom based classification of NETs
4.11.5. Diagnosed prevalent cases based on Malignancy
4.11.6. Site-specific prevalent cases of NETs
4.11.7. Grade-wise prevalent cases of NETs
4.11.8. Stage-wise prevalent cases of NETs
4.12. Japan
4.12.1. Total Prevalent Cases of NETs in Japan
4.12.2. Total Incident Cases of NETs in Japan
4.12.3. Diagnosed prevalent cases of NETs in Japan
4.12.4. Symptom based classification of NETs
4.12.5. Diagnosed prevalent cases based on Malignancy
4.12.6. Site-specific prevalent cases of NETs
4.12.7. Grade-wise prevalent cases of NETs
4.12.8. Stage-wise prevalent cases of NETs
5. Treatment Algorithm
6. Unmet needs
7. Marketed drugs
7.1. Afinitor (Everolimus): Novartis
7.1.1. Product Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Other development activities
7.1.5. Safety and Efficacy
7.1.6. Advantages and Disadvantages
7.1.7. Product Profile
7.2. Sutent (Sunitinib Malate): Pfizer
7.2.1. Product Description
7.2.2. Mechanism of Action
7.2.3. Regulatory Milestones
7.2.4. Other development activities
7.2.5. Safety and Efficacy
7.2.6. Advantages and Disadvantages
7.2.7. Product Profile
7.3. Somatuline Depot (Lanreotide): Ipsen Biopharmaceuticals Inc.
7.3.1. Product Description
7.3.2. Mechanism of Action
7.3.3. Regulatory Milestones
7.3.4. Other development activities
7.3.5. Safety and Efficacy
7.3.6. Product Profile
7.4. Lutathera (lutetium Lu 177 dotatate): Advanced Accelerator Applications S.A.
7.4.1. Product Description
7.4.2. Mechanism of Action
7.4.3. Regulatory Milestones
7.4.4. Other development activities
7.4.5. Safety and Efficacy
7.4.6. Advantages and Disadvantages
7.4.7. Product Profile
8. Emerging drugs
9. Key Cross Competition
9.1. Iobenguane I-131: Progenics Pharmaceuticals
9.1.1. Product Description
9.1.2. Product Profile
9.1.3. Product Development Activities
9.1.4. Clinical development
9.1.5. Safety and Efficacy
9.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
9.2.1. Product Description
9.2.2. Product Profile
9.2.3. Product Development Activities
9.2.4. Clinical development
9.2.5. Safety and Efficacy
9.3. AMG 479: Amgen
9.3.1. Product Description
9.3.2. Product Profile
9.3.3. Product Development Activities
9.3.4. Clinical Development
9.3.5. Safety and Efficacy
9.3.6. Advantages and Disadvantages
9.4. Anlotinib: Advenchen Laboratories
9.4.1. Product Description
9.4.2. Product Profile
9.4.3. Product Development Activities
9.4.4. Clinical Development
9.5. Carfilzomib: Amgen
9.5.1. Product Description
9.5.2. Product Profile
9.5.3. Product Development Activities
9.5.4. Clinical development
9.5.5. Safety and Efficacy
9.6. ATG-008: Antengene
9.6.1. Product Description
9.6.2. Product Profile
9.6.3. Product Development Activities
9.6.4. Clinical development
9.6.5. Safety and Efficacy
9.7. Entrectinib: Ignyta
9.7.1. Product Description
9.7.2. Product Profile
9.7.3. Product Development Activities
9.7.4. Clinical development
9.7.5. Safety and Efficacy
9.8. Fosbretabulin: Mateon Therapeutics
9.8.1. Product Description
9.8.2. Product Profile
9.8.3. Product Development Activities
9.8.4. Clinical development
9.8.5. Safety and Efficacy
9.9. Ipilimumab: Bristol-Myers Squibb
9.9.1. Product Description
9.9.2. Product Profile
9.9.3. Product Development Activities
9.9.4. Clinical development
9.9.5. Advantages and Disadvantages
9.10. Ribociclib: Novartis
9.10.1. Product Description
9.10.2. Product Profile
9.10.3. Product Development Activities
9.10.4. Clinical development
9.10.5. Advantages and Disadvantages
9.11. Pembrolizumab: Merck
9.11.1. Product Description
9.11.2. Product Profile
9.11.3. Clinical development
9.12. RRx-001: EpicentRx
9.12.1. Product Description
9.12.2. Product Profile
9.12.3. Product Development Activities
9.12.4. Clinical development
9.12.5. Safety and Efficacy
9.13. Axitinib: Pfizer
9.13.1. Product Description
9.13.2. Product Profile
9.13.3. Clinical development
9.13.4. Safety and Efficacy
9.14. Cabozantinib: Exelixis
9.15. Product Description
9.16. Product Profile
9.17. Product Development Activities
9.18. Clinical development
9.19. Safety and Efficacy
9.20. CAM2029: Camurus
9.20.1. Product Description
9.20.2. Product Profile
9.20.3. Product Development Activities
9.20.4. Clinical development
9.20.5. Safety and Efficacy
9.21. Atezolizumab and Bevacizumab: Genentech
9.21.1. Product Description
9.21.2. Product Profile
9.21.3. Clinical development
9.22. Lenvatinib: Eisai
9.22.1. Product Description
9.22.2. Product Profile
9.22.3. Clinical Development
9.23. Pasireotide LAR: Novartis
9.23.1. Product Description
9.23.2. Product Profile
9.23.3. Regulatory Milestones
9.23.4. Clinical Development
9.23.5. Safety and Efficacy
9.23.6. Advantages and Disadvantages
9.24. Spartalizumab: Novartis
9.24.1. Product Description
9.24.2. Product Profile
9.24.3. Regulatory Milestones
9.24.4. Clinical Development
9.25. Tirapazamine: Teclison
9.25.1. Product Description
9.25.2. Product Profile
9.25.3. Clinical Development
9.26. Pentarin: Tarveda Therapeutics
9.26.1. Product Description
9.26.2. Product Profile
9.26.3. Regulatory Milestones
9.26.4. Clinical Development
9.26.5. Safety and Efficacy
9.27. Sulfatinib: Hutchison MediPharma
9.27.1. Product Description
9.27.2. Product Profile
9.27.3. Clinical Development
9.27.4. Safety and Efficacy
9.28. Ibrutinib: Pharmacyclics
9.28.1. Product Description
9.28.2. Product Profile
9.28.3. Clinical Development
9.28.4. Advantages and Disadvantages
9.29. Ramucirumab: Eli Lilly
9.29.1. Product Description
9.29.2. Product Profile
9.29.3. Clinical Development
9.29.4. Advantages and Disadvantages
9.30. ALT 803: Altor Biosciences
9.30.1. Product Description
9.30.2. Product Profile
9.30.3. Regulatory Milestones
9.30.4. Clinical Development
9.31. Talimogene laherparepvec: Amgen
9.31.1. Product Description
9.31.2. Product Profile
9.31.3. Clinical Development
9.32. Netazepide: Trio Medicines
9.32.1. Product Description
9.32.2. Product Profile
9.32.3. Clinical Development
9.32.4. Safety and Efficacy
9.32.5. Advantages and Disadvantages
10. Neuroendocrine Tumors: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of Neuroendocrine Tumors (NETs) in 7MM
10.3. Market Outlook by Country
10.4. The United States: Market Outlook
10.4.1. United States Market Size
10.4.2. Total Market size of NETs
10.4.3. Market Size by Therapies
10.5. EU-5 Countries: Market Outlook
10.6. Germany
10.6.1. Total Market size of NETs
10.6.2. Market Size by Therapies
10.7. France
10.7.1. Total Market size of NETs
10.7.2. Market Size by Therapies
10.8. United Kingdom
10.8.1. Total Market size of NETs
10.8.2. Market Size by Therapies
10.9. Spain
10.9.1. Total Market size of NETs
10.9.2. Market Size by Therapies
10.10. Italy
10.10.1. Total Market size of NETs
10.10.2. Market Size by Therapies
10.11. Japan: Market Outlook
10.11.1. Total Market size of NETs
10.11.2. Market Size by Therapies
11. Market Drivers
12. Market Barriers
13. Appendix
13.1. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
List Of Tables
Table 1: Clinical syndrome of functional and non-functional pancreatic neuroendocrine tumors
Table 2: Systems of nomenclature for NETs
Table 3: Grading systems for NETs
Table 4: Total Prevalent Population of NETs in the 7MM (2016-2027)
Table 5: Total Incident Population of NETs in the 7MM (2016-2027)
Table 6: Total Prevalent Cases of NETs in the United States (2016-2027)
Table 7: Total Incident Cases of NETs in the United States (2016-2027)
Table 8: Diagnosed prevalent cases of NETs in the United States (2016-2027)
Table 9: Symptom based classification of NETs in the United States (2016-2027)
Table 10: Diagnosed prevalent cases based on Malignancy in the United States (2016-2027)
Table 11: Site-specific prevalent cases of NETs in the United States (2016-2027)
Table 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
Table 13: Stage-wise prevalent cases of NETs in the United States (2016-2027)
Table 14: Total Prevalent Cases of NETs in Germany (2016-2027)
Table 15: Total Incident Cases of NETs in Germany (2016-2027)
Table 16: Diagnosed prevalent cases of NETs in Germany (2016-2027)
Table 17: Symptom based classification of NETs in Germany (2016-2027)
Table 18: Diagnosed prevalent cases based on Malignancy in Germany (2016-2027)
Table 19: Site-specific prevalent cases of NETs in Germany (2016-2027)
Table 20: Grade-wise prevalent cases of NETs in Germany (2016-2027)
Table 21: Stage-wise prevalent cases of NETs in Germany (2016-2027)
Table 22: Total Prevalent Cases of NETs in France (2016-2027)
Table 23: Total Incident Cases of NETs in France (2016-2027)
Table 24: Diagnosed prevalent cases of NETs in France (2016-2027)
Table 25: Symptom based classification of NETs in France (2016-2027)
Table 26: Diagnosed prevalent cases based on Malignancy in France (2016-2027)
Table 27: Site-specific prevalent cases of NETs in France (2016-2027)
Table 28: Grade-wise prevalent cases of NETs in France (2016-2027)
Table 29: Stage-wise prevalent cases of NETs in France (2016-2027)
Table 30: Total Prevalent Cases of NETs in Italy (2016-2027)
Table 31: Total Incident Cases of NETs in Italy (2016-2027)
Table 32: Diagnosed prevalent cases of NETs in Italy (2016-2027)
Table 33: Symptom based classification of NETs in Italy (2016-2027)
Table 34: Diagnosed prevalent cases based on Malignancy in Italy (2016-2027)
Table 35: Site-specific prevalent cases of NETs in Italy (2016-2027)
Table 36: Grade-wise prevalent cases of NETs in Italy (2016-2027)
Table 37: Stage-wise prevalent cases of NETs in Italy (2016-2027)
Table 38: Total Prevalent Cases of NETs in Spain (2016-2027)
Table 39: Total Incident Cases of NETs in Spain (2016-2027)
Table 40: Diagnosed prevalent cases of NETs in Spain (2016-2027)
Table 41: Symptom based classification of NETs in Spain (2016-2027)
Table 42: Diagnosed prevalent cases based on Malignancy in Spain (2016-2027)
Table 43: Site-specific prevalent cases of NETs in Spain (2016-2027)
Table 44: Grade-wise prevalent cases of NETs in Spain (2016-2027)
Table 45: Stage-wise prevalent cases of NETs in Spain (2016-2027)
Table 46: Total Prevalent Cases of NETs in the UK (2016-2027)
Table 47: Total Incident Cases of NETs in the UK (2016-2027)
Table 48: Diagnosed prevalent cases of NETs in the UK (2016-2027)
Table 49: Symptom based classification of NETs in the UK (2016-2027)
Table 50: Diagnosed prevalent cases based on Malignancy in the UK (2016-2027)
Table 51: Site-specific prevalent cases of NETs in the UK(2016-2027)
Table 52: Grade-wise prevalent cases of NETs in the UK (2016-2027)
Table 53: Stage-wise prevalent cases of NETs in the UK (2016-2027)
Table 54: Total Prevalent Cases of NETs in Japan (2016-2027)
Table 55: Total Incident Cases of NETs in Japan (2016-2027)
Table 56: Diagnosed prevalent cases of NETs in Japan (2016-2027)
Table 57: Symptom based classification of NETs in Japan (2016-2027)
Table 58: Diagnosed prevalent cases based on Malignancy in Japan (2016-2027)
Table 59: Site-specific prevalent cases of NETs in Japan (2016-2027)
Table 60: Grade-wise prevalent cases of NETs in Japan (2016-2027)
Table 61: Stage-wise prevalent cases of NETs in Japan (2016-2027)
Table 62: Lenvatinib, Clinical Trial Description, 2018
Table 63: Pasireotide, Clinical Trial Description, 2018
Table 64: Spartalizumab, Clinical Trial Description, 2018
Table 65: Tirapazamine, Clinical Trial Description, 2018
Table 66: Pentarin, Clinical Trial Description, 2018
Table 67: Sulfatinib, Clinical Trial Description, 2018
Table 68: Ibrutinib, Clinical Trial Description, 2018
Table 69: Ramucirumab, Clinical Trial Description, 2018
Table 70: ALT 803, Clinical Trial Description, 2018
Table 71: Talimogene laherparepvec, Clinical Trial Description, 2018
Table 72: Netazepide, Clinical Trial Description, 2018
Table 73: 7 Major Market Size of NETs in USD Million (2016-2027)
Table 74: The US Market Size of NETs in USD Million (2016-2027)
Table 75: Therapies Based market of NETs in the US, in USD Million (2016-2027)
Table 76: Market Size of NETs in Germany, in USD Million (2016-2027)
Table 77: Therapies Based market of NETs in Germany, in USD Million (2016-2027)
Table 78: Market Size of NETs in France, in USD Million (2016-2027)
Table 79: Therapies Based market of NETs in France, in USD Million (2016-2027)
Table 80: Market Size of NETs in the UK, in USD Million (2016-2027)
Table 81: Therapies Based market of NETs in the UK, in USD Million (2016-2027)
Table 82: Market Size of NETs in Spain, in USD Million (2016-2027)
Table 83: Therapies Based market of NETs in Spain, in USD Million (2016-2027)
Table 84: Market Size of NETs in Italy, in USD Million (2016-2027)
Table 85: Therapies Based market of NETs in Italy, in USD Million (2016-2027)
Table 86: Market Size of NETs in Japan, in USD Million (2016-2027)
Table 87:Therapies Based market of NETs in Japan, in USD Million (2016-2027)
List Of Figures
Figure 1: Classification of Neuroendocrine Tumors
Figure 2: Causes of Neuroendocrine Tumors
Figure 3: Targeting critical signaling pathways in NETs
Figure 4: Total Prevalent Population of NETs in the 7MM (2016-2027)
Figure 5: Total Incident Population of NETs in the 7MM (2016-2027)
Figure 6: Total Prevalent cases of NETs in the United States (2016-2027)
Figure 7: Total Incident cases of NETs in the United States (2016-2027)
Figure 8: Diagnosed prevalent cases of NETs in the United States (2016-2027)
Figure 9: Symptom based classification of NETs in the United States (2016-2027)
Figure 10: Diagnosed prevalent cases based on Malignancy in the United States (2016-2027)
Figure 11: Site-specific prevalent cases of NETs in the United States (2016-2027)
Figure 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
Figure 13: Stage-wise prevalent cases of NETs in the United States (2016-2027)
Figure 14: Total Prevalent cases of NETs in Germany (2016-2027)
Figure 15: Total Incident cases of NETs in Germany (2016-2027)
Figure 16: Diagnosed prevalent cases of NETs in Germany (2016-2027)
Figure 17: Symptom based classification of NETs in Germany (2016-2027)
Figure 18: Diagnosed prevalent cases based on Malignancy in Germany (2016-2027)
Figure 19: Site-specific prevalent cases of NETs in Germany (2016-2027)
Figure 20: Grade-wise prevalent cases of NETs in Germany (2016-2027)
Figure 21: Stage-wise prevalent cases of NETs in Germany (2016-2027)
Figure 22: Total Prevalent cases of NETs in the France (2016-2027)
Figure 23: Total Incident cases of NETs in the France (2016-2027)
Figure 24: Diagnosed prevalent cases of NETs in France (2016-2027)
Figure 25: Symptom based classification of NETs in France (2016-2027)
Figure 26: Diagnosed prevalent cases based on Malignancy in France (2016-2027)
Figure 27: Site-specific prevalent cases of NETs in France (2016-2027)
Figure 28: Grade-wise prevalent cases of NETs in France (2016-2027)
Figure 29: Stage-wise prevalent cases of NETs in France (2016-2027)
Figure 30: Total Prevalent cases of NETs in Italy (2016-2027)
Figure 31: Total Incident cases of NETs in Italy (2016-2027)
Figure 32: Diagnosed prevalent cases of NETs in Italy (2016-2027)
Figure 33: Symptom based classification of NETs in Italy (2016-2027)
Figure 34: Diagnosed prevalent cases based on Malignancy in Italy (2016-2027)
Figure 35: Site-specific prevalent cases of NETs in Italy (2016-2027)
Figure 36: Grade-wise prevalent cases of NETs in Italy (2016-2027)
Figure 37: Stage-wise prevalent cases of NETs in Italy (2016-2027)
Figure 38: Total Prevalent cases of NETs in the Spain (2016-2027)
Figure 39: Total Incident cases of NETs in the Spain (2016-2027)
Figure 40: Diagnosed prevalent cases of NETs in Spain (2016-2027)
Figure 41: Symptom based classification of NETs in Spain (2016-2027)
Figure 42: Diagnosed prevalent cases based on Malignancy in Spain (2016-2027)
Figure 43: Site-specific prevalent cases of NETs in Spain (2016-2027)
Figure 44: Grade-wise prevalent cases of NETs in Spain (2016-2027)
Figure 45: Stage-wise prevalent cases of NETs in Spain (2016-2027)
Figure 46: Total Prevalent cases of NETs in the UK (2016-2027)
Figure 47: Total Incident cases of NETs in the UK (2016-2027)
Figure 48: Diagnosed prevalent cases of NETs in the UK (2016-2027)
Figure 49: Symptom based classification of NETs in the UK (2016-2027)
Figure 50: Diagnosed prevalent cases based on Malignancy in the UK (2016-2027)
Figure 51: Site-specific prevalent cases of NETs in the UK (2016-2027)
Figure 52: Grade-wise prevalent cases of NETs in the UK (2016-2027)
Figure 53: Stage-wise prevalent cases of NETs in the UK (2016-2027)
Figure 54: Total Prevalent cases of NETs in Japan (2016-2027)
Figure 55: Total Incident cases of NETs in Japan (2016-2027)
Figure 56: Diagnosed prevalent cases of NETs in Japan (2016-2027)
Figure 57: Symptom based classification of NETs in the Japan (2016-2027)
Figure 58: Diagnosed prevalent cases based on Malignancy in Japan (2016-2027)
Figure 59: Site-specific prevalent cases of NETs in Japan (2016-2027)
Figure 60: Grade-wise prevalent cases of NETs in Japan (2016-2027)
Figure 61: Stage-wise prevalent cases of NETs in Japan (2016-2027)
Figure 62: Treatment of Neuroendocrine tumors
Figure 63: Unmet needs
Figure 64: 7 Major Market Size of NETs in USD Million (2016-2027)
Figure 65: Market Size of NETs in the US, USD (2016-2027)
Figure 66: Therapies Based market of NETs in the US in USD Million (2016-2027)
Figure 67: Market Size of NETs in Germany, USD Million (2016-2027)
Figure 68: Therapies Based market of NETs in Germany, in USD Million (2016-2027)
Figure 69: Market Size of NETs in France, USD Million (2016-2027)
Figure 70: Therapies Based market of NETs in France, in USD Million (2016-2027)
Figure 71: Market Size of NETs in the UK, USD Million (2016-2027)
Figure 72: Therapies Based market of NETs in the UK, in USD Million (2016-2027)
Figure 73: Market Size of NETs in Spain, USD Million (2016-2027)
Figure 74: Therapies Based market of NETs in Spain, in USD Million (2016-2027)
Figure 75: Market Size of NETs in Italy, USD Million (2016-2027)
Figure 76: Therapies Based market of NETs in Italy, in USD Million (2016-2027)
Figure 77: Market Size of NETs in Japan, USD Million (2016-2027)
Figure 78: Therapies Based market of NETs in Japan, in USD Million (2016-2027)
Figure 79: Market Drivers
Figure 80:Market Barriers

DelveInsight’s ‘Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NETs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Neuroendocrine Tumors from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
-The United States
-EU5 (Germany, France, Italy, Spain and the United Kingdom)
-Japan

Study Period: 2016-2027

Neuroendocrine Tumors (NETs) - Disease Understanding and Treatment Algorithm
The DelveInsight Neuroendocrine Tumors market report gives the thorough understanding of the NETs by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuroendocrine Tumors in the US, Europe, and Japan.

Neuroendocrine Tumors Epidemiology
The Neuroendocrine Tumors epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, total incident cases, diagnosed prevalent cases, symptom based classification of NETs (asymptomatic and symptomatic), diagnosed prevalence based on malignancy (Malignant and non-malignant), site specific incident cases (Gastroenteropancreatic, lung and other sites), Grade-wise prevalent cases (Grade I, Grade II and Grade III) and stage-wise prevalent cases (localized, regional and distant)] scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the total prevalent population of Neuroendocrine Tumors (NETs) was found to be 442,100 in the year 2016 in 7MM.

Neuroendocrine Tumors Drug Chapters
This segment of the NETs report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Medications, including chemotherapy and cytotoxic agents are considered after surgery for NETs treatment. The somatostatin analogs, octreotide and lanreotide remain the keystone of treatment. Cytotoxic therapies such as streptozocin, 5-FU, or temozolomide are considered in the palliation of patients with advanced pancreatic NET and symptoms related to tumor bulk. For the distant tumors that have grown outside where regional therapies don’t work, systemic therapies are the options for treatment, Everliomus is an effective targeted therapy that acts as mTOR inhibitor, sunitinib is the only orally available tyrosine kinase inhibitor and radiolabeled somatostatin analog therapies are generally considered. Detailed chapter for upcoming therapies like Azedra (Progenics Pharmaceuticals), 177Lu-edotreotide PRRT (ITM Isotopen Technologien Muenchen), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001 (EpicentRx), Entrectinib (Ignyta), AMG-479 (Amgen), Carfilzomib (Amgen), ATG-008 (Antengene) and Fosbretabulin (Mateon Therapeutics) have been covered in the report.

Neuroendocrine Tumors Market Outlook
The Neuroendocrine Tumors market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Neuroendocrine Tumors in 7MM was found to be USD 3.45 billion in 2016.

Neuroendocrine Tumors Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neuroendocrine Tumors Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
• Neuroendocrine Tumors Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Neuroendocrine Tumors Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Neuroendocrine Tumors market
• Organize sales and marketing efforts by identifying the best opportunities for Neuroendocrine Tumors market
• To understand the future market competition in the Neuroendocrine Tumors market


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;